Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonepcizumab + aflibercept
- Development stage
- Preclinical
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
**sonepcizumab + aflibercept** is a combination drug consisting of sonepcizumab and aflibercept. Aflibercept is a recombinant fusion protein that acts as a potent inhibitor of vascular endothelial growth factor (VEGF), blocking VEGF-A, VEGF-B, and placental growth factor (PlGF). This action reduces abnormal blood vessel growth and vascular permeability in the eye[1][5]. Sonepcizumab is a monoclonal antibody targeting sphingosine-1-phosphate (S1P), which is involved in angiogenesis and vascular permeability. The combination is investigated for enhanced efficacy in conditions involving neovascularization, notably wet age-related macular degeneration (AMD).
- Other names
- VEGF Trap-Eye
02
Targets
VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)S1P (Site-1 protease)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on sonepcizumab + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonepcizumab + aflibercept.